[DVAX] Dynavax Technologies Corporation


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 547.86 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 4.1 Change: 0.05 (1.23%)
Ext. hours: Change: 0 (0%)

chart DVAX

Refresh chart

Strongest Trends Summary For DVAX

DVAX is in the medium-term down -20% below S&P in 2 months. In the long-term down -52% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases, and cancer. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a investigational adult hepatitis B vaccine which is in Phase III clinical trials. The company also develops DV1179, a TLR inhibitor of TLR 7 and TLR9 for the treatment of autoimmune and inflammatory diseases that is in Phase I clinical trials; AZD1419, a candidate drug for the treatment of asthma, which is in Phase I clinical trials; SD-101, a second-generation TLR 9 agonist for immunotherapy of cancer that is in Phase I clinical trials; and DV230, an adjuvant platform that is in preclinical studies. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the d

Fundamental Ratios
Shares Outstanding38.5 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -79.43% Sales Growth - Q/Q-72.46% P/E
P/E To EPS Growth P/S67.13 P/BV7.3 Price/Cash Per Share5.61
Price/Free Cash Flow-7.27 ROA-91.91% ROE-137.33% ROI
Current Ratio4.97 Quick Ratio Long Term Debt/Equity Debt Ratio0.27
Gross Margin Operating Margin-1271.85% Net Profit Margin-1263.31% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities140 K Cash From Investing Activities-10.52 M Cash From Operating Activities-24.14 M Gross Profit
Net Profit-26.22 M Operating Profit-26.45 M Total Assets112.17 M Total Current Assets101.98 M
Total Current Liabilities20.5 M Total Debt9.51 M Total Liabilities37.1 M Total Revenue630 K
Technical Data
High 52 week20.75 Low 52 week8.14 Last close10.36 Last change-1.05%
RSI39.48 Average true range0.47 Beta1.07 Volume1.13 M
Simple moving average 20 days-3.3% Simple moving average 50 days-0.55% Simple moving average 200 days-19.85%
Performance Data
Performance Week-6.92% Performance Month-3.09% Performance Quart-10.3% Performance Half-22.97%
Performance Year-37.78% Performance Year-to-date13.22% Volatility daily2.34% Volatility weekly5.23%
Volatility monthly10.72% Volatility yearly37.14% Relative Volume185.36% Average Volume949.67 K
New High New Low


2019-03-21 06:30:00 | HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results

2019-03-20 16:20:00 | Dynavax to Present on Inhaled TLR9 Agonist DV281 at the AACR Annual Meeting 2019

2019-03-18 16:05:00 | Dynavax Exercises Option for $75 Million in Non-Dilutive Debt

2019-03-07 09:44:00 | Why Dynavax Technologies Cratered in February

2019-03-06 16:05:00 | Dynavax to Present at 39th Annual Cowen Healthcare Conference

2019-03-01 09:00:57 | Should You Be Concerned About Dynavax Technologies Corporation’s NASDAQ:DVAX Historical Volatility?

2019-02-27 03:06:17 | Edited Transcript of DVAX earnings conference call or presentation 26-Feb-19 9:30pm GMT

2019-02-26 22:40:17 | Dynavax Technologies Corporation DVAX Q4 2018 Earnings Conference Call Transcript

2019-02-26 16:05:00 | Dynavax Announces Fourth Quarter and Full Year 2018 Financial Results

2019-02-12 16:05:00 | Dynavax Technologies to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26

2019-02-11 07:20:00 | Recent Analysis Shows Corcept Therapeutics, CDK Global, Dynavax Technologies, ICU Medical, American Vanguard, and Cabot Market Influences — Renewed Outlook, Key Drivers of Growth

2019-02-10 13:00:00 | Why Dynavax Technologies Stock Marched Higher in January

2019-01-29 16:05:00 | Heather Rowe Named Dynavax’s Vice President of Investor Relations and Corporate Communications

2019-01-16 08:00:00 | Today's Research Reports on Trending Tickers: Dynavax Technologies and Tyme Technologies

2019-01-15 17:00:00 | Why Dynavax Technologies Stock Fell 51% in 2018

2019-01-15 12:18:08 | Is Dynavax Technologies Corporation NASDAQ:DVAX Worth US$10.80 Based On Intrinsic Value?

2019-01-09 10:07:00 | 2 Small-Caps That Should Continue to Stage Comebacks in 2019

2019-01-08 09:00:00 | Sam’s Club and Dynavax Technologies Corporation Announce Collaboration to Make HEPLISAV-B® Available to Sam’s Club Patients

2019-01-07 08:17:00 | Here's Why Dynavax Technologies Slid 19% in December

2019-01-03 16:05:00 | Dynavax to Present at 37th Annual J.P. Morgan Healthcare Conference

2018-12-30 15:27:08 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

2018-12-17 01:38:54 | Is Dynavax Technologies Corporation DVAX Going to Burn These Hedge Funds?

2018-11-12 15:37:00 | Why Dynavax Technologies Corporation Fell 20.2% in October

2018-11-08 08:55:00 | Consolidated Research: 2018 Summary Expectations for MYR Group, L.B. Foster, The Habit Restaurants, Viper Energy Partners LP, Twin Disc, and Dynavax Technologies — Fundamental Analysis, Key Performance Indications

2018-11-06 01:09:51 | Edited Transcript of DVAX earnings conference call or presentation 5-Nov-18 9:30pm GMT

2018-11-05 17:39:18 | Dynavax Technologies: 3Q Earnings Snapshot

2018-11-05 16:01:00 | Dynavax Reports Third Quarter 2018 Financial Results, Progress on HEPLISAV-B Launch, and Updated SD-101 Data in Three Patient Populations

2018-11-05 15:00:00 | Don't Waste Your Money on Penny Stocks; These 3 Stocks Are Better Buys

2018-10-29 06:00:00 | Dynavax to Host Third Quarter 2018 Financial Results Conference Call

2018-10-26 10:30:02 | Dynavax Technologies DVAX Q3 Earnings Preview: What to Watch Ahead of the Release

2018-10-24 08:41:12 | Dynavax DVAX Catches Eye: Stock Jumps 9.8%

2018-10-22 16:29:00 | Why American Railcar Industries, PetMed Express, and Dynavax Technologies Jumped Today

2018-10-22 10:23:00 | Why Dynavax Technologies Corporation Is Surging Today

2018-10-20 08:45:00 | Dynavax’s SD-101 in Combination with KEYTRUDA® pembrolizumab Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at the ESMO 2018 Congress

2018-10-18 11:05:00 | Medical Companies You Need to Have on Your Radar

2018-10-17 07:20:00 | Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis — Discovering Underlying Factors of Influence

2018-10-15 06:00:00 | Dynavax Technologies and Quantum Leap Healthcare Collaborative Announce Selection of SD-101 Combined with KEYTRUDA® pembrolizumab in the I-SPY 2 TRIAL For Breast Cancer

2018-10-14 13:21:15 | The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs

2018-10-10 10:30:00 | Major Biotech Announcements Moving the Market

2018-10-09 10:45:41 | ARWR Stock Sinks After Signing a Big Collaboration Deal

2018-10-09 06:00:00 | Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® pembrolizumab at the European Society for Medical Oncology 2018 Congress

2018-10-03 11:26:00 | Why Dynavax Technologies Corporation Stock Struggled in September

2018-10-01 09:52:15 | Health Care Digest: An East Bay biotech coup, a Nobel effort and an A's bobblehead

2018-09-29 18:31:18 | 3 Top Stocks That Aren't on Wall Street's Radar

2018-09-27 16:01:00 | Dynavax to Present at the 2018 Cantor Global Healthcare Conference

2018-09-04 06:30:00 | Dynavax Announces Publication of Preclinical Study of TLR9 Agonist in Lung Cancer

2018-08-28 06:30:00 | Dynavax Announces Publication of Two Papers in Leading Oncology Journal Highlighting Data From Clinical Studies of Its TLR9 Agonist, SD-101

2018-08-19 09:01:00 | Is Dynavax Technologies Corporation a Buy?

2018-08-16 08:44:00 | Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation

2018-08-14 07:45:00 | Consolidated Research: 2018 Summary Expectations for National Instruments, Dynavax Technologies, BWX Technologies, Fossil Group, GCP Applied Technologies, and Stratasys — Fundamental Analysis, Key Performance Indications